Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad pipeline across kidney disease, neuropathic pain, type 1 diabetes and other serious conditions. The VRTX news feed on Stock Titan brings together company press releases and other coverage that highlight how its commercial portfolio and research programs are evolving over time.
News about Vertex often focuses on clinical data readouts, regulatory milestones and commercial updates. Recent announcements have covered progress in cystic fibrosis, including data on ALYFTREK and other CFTR modulators presented at scientific conferences, and updates on next-generation CFTR correctors and CFTR mRNA therapies. Vertex also regularly reports on CASGEVY, its CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, including longer-term outcomes data and plans for regulatory submissions in additional age groups.
Investors and followers of VRTX news can also expect updates on JOURNAVX, the company’s oral non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in adults, including information on prescription trends, payer coverage and hospital formulary adoption. In kidney diseases, Vertex issues news on povetacicept and inaxaplin, including Phase 1/2 and Phase 3 trial data in IgA nephropathy, primary membranous nephropathy and APOL1-mediated kidney disease, as well as regulatory designations such as Breakthrough Therapy and Fast Track.
Additional news items may include financial results, participation in major healthcare investor conferences, and updates on programs in type 1 diabetes, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. For anyone tracking VRTX stock, this news page offers a centralized view of how Vertex’s marketed products and pipeline advance through clinical development, regulatory review and commercialization.
Vertex (NASDAQ: VRTX) presented multiple abstracts at the North American Cystic Fibrosis Conference (October 22–25, 2025, Seattle) showing clinical benefits from CFTR modulators, including newly approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor).
Key findings: Phase 3 data (SKYLINE 102/103) show ALYFTREK produced greater reductions in sweat chloride versus TRIKAFTA and lower rates of pulmonary exacerbations and IV antibiotic use in F508del/minimal function genotypes. Pooled analyses (>2,000 participants) link achieving SwCl thresholds (<60 mmol/L and <30 mmol/L) to reduced annual antibiotic use. Younger treatment (ages 6–11) showed larger CFTR function gains and broader clinical benefits.
Vertex (Nasdaq: VRTX) announced regulatory and clinical progress for povetacicept (pove), a BAFF+APRIL dual antagonist for B cell–mediated kidney diseases. The FDA granted a rolling review of the BLA for pove in IgA nephropathy (IgAN); Vertex expects to submit the first module before the end of 2025 and aims to complete the full BLA in H1 2026 if an interim analysis is supportive. Vertex also initiated OLYMPUS, a Phase 2b/3 pivotal trial in primary membranous nephropathy (pMN). Multiple data presentations, including a late-breaking RUBY-3 oral on Nov 8, 2025, are planned at ASN Kidney Week (Nov 6–9, 2025).
Vertex (Nasdaq: VRTX) will report third quarter 2025 financial results on Monday, November 3, 2025 after market close. The company will host a conference call and live webcast at 4:30 p.m. ET.
Participants may dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and should reference "Vertex Pharmaceuticals Third Quarter 2025 Earnings Call." The live webcast and an archived replay will be available in the Investors section at www.vrtx.com. Registration at least 15 minutes before the webcast is recommended.
Vertex Pharmaceuticals (NASDAQ:VRTX) announced significant progress across its kidney disease portfolio. The FDA granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy, with potential accelerated approval filing in H1 2026. The company completed enrollment for the interim analysis cohort of the AMPLITUDE Phase 2/3 trial studying inaxaplin in APOL1-mediated kidney disease.
Additionally, Vertex initiated AGLOW, a Phase 2 proof-of-concept study for VX-407 in autosomal dominant polycystic kidney disease (ADPKD). VX-407 is designed to treat approximately 10% of the ADPKD population with specific PKD1 variants by correcting defective PC1 folding to restore function.
Vertex Pharmaceuticals (Nasdaq: VRTX) has announced a partnership with basketball world champion Jayson Tatum to promote JOURNAVX®, their FDA-approved non-opioid medication for moderate-to-severe acute pain treatment. The partnership highlights Tatum's personal experience using JOURNAVX while recovering from an Achilles tendon injury during the 2025 playoffs.
Tatum chose JOURNAVX as an alternative after experiencing side effects from traditional opioid pain medication following his surgery. Dr. Martin J. O'Malley, Clinical Professor at the Hospital for Special Surgery, confirmed the medication's effectiveness in managing Tatum's post-operative pain. JOURNAVX represents the first new class of pain medicine approved in over 20 years.
Vertex Pharmaceuticals (NASDAQ:VRTX) has secured a reimbursement agreement with the Italian Medicines Agency (AIFA) for CASGEVY®, its CRISPR/Cas9 gene-edited therapy. The agreement covers eligible patients with transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).
Italy represents a significant market with approximately 5,000 people aged 12 and older living with TDT and 2,300 with SCD, marking the largest TDT population in Europe. This agreement adds Italy to the growing list of countries providing reimbursement for CASGEVY, including Austria, Bahrain, Denmark, England, Saudi Arabia, and the UAE.
Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Senior Vice President Paul Negulescu has been awarded the prestigious 2025 Lasker~DeBakey Clinical Medical Research Award. The recognition comes for his pivotal role in developing TRIKAFTA®, a groundbreaking triple-drug combination therapy for cystic fibrosis (CF).
Dr. Negulescu shares the award with former Vertex scientist Jesús González and University of Iowa Professor Michael Welsh. The award acknowledges Vertex's achievements in developing five transformational medicines that address the underlying cause of CF, including TRIKAFTA® and ALYFTREK®, which have revolutionized CF treatment for thousands of patients worldwide.
Vertex Pharmaceuticals (NASDAQ:VRTX) has entered into a strategic collaboration with Enlaza Therapeutics to leverage Enlaza's proprietary War-Lock™ technology platform for developing covalent biologics. The partnership focuses on creating small format drug conjugates and T-cell engagers for autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia treatments.
The collaboration includes a $45 million initial investment combining upfront payment and equity investment, with potential for over $2 billion in milestone payments plus tiered royalties. Enlaza will lead research through candidate nomination, while Vertex will manage subsequent development, manufacturing, and commercialization. The four-year collaboration's research and development costs will be funded by Vertex.
This partnership aims to enhance Vertex's CASGEVY® therapy, the first approved CRISPR/Cas9 gene-edited treatment, by developing gentler conditioning methods.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced its management team's participation in three major healthcare investor conferences in September 2025. The company's executives will participate in fireside chats at the Wells Fargo Healthcare Conference (September 3), Morgan Stanley Global Healthcare Conference (September 9), and Bank of America Global Healthcare Conference in London (September 23).
Key participants include CEO Reshma Kewalramani, Chief Commercial Officer Duncan McKechnie, and Senior VP of Investor Relations Susie Lisa. All sessions will be available via webcast on Vertex's website with replays archived in the Investors section.
Vertex Pharmaceuticals (NASDAQ:VRTX) announced disappointing topline results from its Phase 2 study of VX-993, a selective NaV1.8 pain signal inhibitor for acute pain treatment. The study, involving 367 patients undergoing bunionectomy surgery, failed to meet its primary endpoint of demonstrating statistically significant improvement in pain reduction (SPID48) compared to placebo.
The trial tested three dosage levels of VX-993 against placebo and a hydrocodone/acetaminophen reference arm. While the drug was generally safe and well-tolerated with no serious adverse events, Vertex will not advance VX-993 into pivotal development as monotherapy in acute pain due to its failure to show superior efficacy compared to existing NaV1.8 inhibitors.
FAQ
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
What is the market cap of Vertex Pharmaceuticals (VRTX)?
